>Dew and others, other than living with chest pain or undergoing TVR/CABG, what are the options for treating ~25% of patients with BMS who will suffer restenosis?<
In some cases, TVR is necessary but, in other cases, drug therapy may be sufficient and less risky (although less profitable to the cardiologist).
>you are assuming that the thrombosis risk with DES will not fall off with time, but this is an unknown.<
I’m merely assuming that thrombosis remains an issue indefinitely—not that the risk is necessarily a constant function with respect to time. Until such time that clinical data can tell me when thrombosis is no longer an issue, I think it’s reasonable to assume that the risk is indefinite.
Market Data 
Markets 
